JP2008520712A

JP2008520712A - ピリミジン化合物及びその使用

ピリミジン化合物及びその使用 Download PDF

Info

Publication number: JP2008520712A
Authority: JP; Japan
Prior art keywords: compound; disease; alkyl; heteroaryl; aryl
Prior art date: 2004-11-19
Legal status : Pending

Application number

JP2007543302A

Other languages

English (en)

Japanese (ja)

Other versions

JP2008520712A5 (https=

Inventor

裕美子和田

ロンツェンリュー

アルバートワイ．シァ

Original Assignee

シンタファーマシューティカルズコーポレーション

Priority date

2004-11-19

Filing date

2005-11-18

Publication date

2008-06-19

2005-11-18 Application filed by シンタファーマシューティカルズコーポレーション filed Critical シンタファーマシューティカルズコーポレーション

2008-06-19 Publication of JP2008520712A publication Critical patent/JP2008520712A/ja

2009-01-15 Publication of JP2008520712A5 publication Critical patent/JP2008520712A5/ja

Status Pending legal-status Critical Current

Links

150000003230 pyrimidines Chemical class 0.000 title description 14
150000001875 compounds Chemical class 0.000 claims abstract description 95
238000000034 method Methods 0.000 claims abstract description 84
108010065805 Interleukin-12 Proteins 0.000 claims abstract description 39
102000013462 Interleukin-12 Human genes 0.000 claims abstract description 39
150000003839 salts Chemical class 0.000 claims abstract description 28
208000023275 Autoimmune disease Diseases 0.000 claims abstract description 25
239000000651 prodrug Substances 0.000 claims abstract description 22
229940002612 prodrug Drugs 0.000 claims abstract description 22
239000012453 solvate Substances 0.000 claims abstract description 18
208000037979 autoimmune inflammatory disease Diseases 0.000 claims abstract description 17
108010066979 Interleukin-27 Proteins 0.000 claims abstract description 15
238000004519 manufacturing process Methods 0.000 claims abstract description 12
-1 R 3 is R c Chemical group 0.000 claims description 80
125000003118 aryl group Chemical group 0.000 claims description 34
229910052717 sulfur Inorganic materials 0.000 claims description 34
125000001072 heteroaryl group Chemical group 0.000 claims description 33
125000000217 alkyl group Chemical group 0.000 claims description 32
210000004027 cell Anatomy 0.000 claims description 30
229910052760 oxygen Inorganic materials 0.000 claims description 20
229910052757 nitrogen Inorganic materials 0.000 claims description 19
229910052799 carbon Inorganic materials 0.000 claims description 18
206010052779 Transplant rejections Diseases 0.000 claims description 16
208000006673 asthma Diseases 0.000 claims description 15
238000006243 chemical reaction Methods 0.000 claims description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
230000002401 inhibitory effect Effects 0.000 claims description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
210000000056 organ Anatomy 0.000 claims description 15
230000001684 chronic effect Effects 0.000 claims description 13
201000010099 disease Diseases 0.000 claims description 13
230000002757 inflammatory effect Effects 0.000 claims description 13
208000011580 syndromic disease Diseases 0.000 claims description 13
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims description 11
229940125797 compound 12 Drugs 0.000 claims description 11
206010020751 Hypersensitivity Diseases 0.000 claims description 10
125000004122 cyclic group Chemical group 0.000 claims description 10
125000000623 heterocyclic group Chemical group 0.000 claims description 10
210000001519 tissue Anatomy 0.000 claims description 10
208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 9
208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 9
201000004624 Dermatitis Diseases 0.000 claims description 9
206010015150 Erythema Diseases 0.000 claims description 9
208000012654 Primary biliary cholangitis Diseases 0.000 claims description 9
125000003342 alkenyl group Chemical group 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 9
150000002367 halogens Chemical class 0.000 claims description 9
125000004076 pyridyl group Chemical group 0.000 claims description 9
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
208000003456 Juvenile Arthritis Diseases 0.000 claims description 8
206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 8
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 8
208000019069 chronic childhood arthritis Diseases 0.000 claims description 8
231100000321 erythema Toxicity 0.000 claims description 8
201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 8
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 8
208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 7
206010039710 Scleroderma Diseases 0.000 claims description 7
206010040047 Sepsis Diseases 0.000 claims description 7
206010047115 Vasculitis Diseases 0.000 claims description 7
125000000304 alkynyl group Chemical group 0.000 claims description 7
208000026935 allergic disease Diseases 0.000 claims description 7
206010028417 myasthenia gravis Diseases 0.000 claims description 7
208000012657 Atopic disease Diseases 0.000 claims description 6
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 6
206010010741 Conjunctivitis Diseases 0.000 claims description 6
206010012442 Dermatitis contact Diseases 0.000 claims description 6
208000017701 Endocrine disease Diseases 0.000 claims description 6
206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 6
206010024229 Leprosy Diseases 0.000 claims description 6
208000019693 Lung disease Diseases 0.000 claims description 6
206010029164 Nephrotic syndrome Diseases 0.000 claims description 6
201000004681 Psoriasis Diseases 0.000 claims description 6
230000008859 change Effects 0.000 claims description 6
208000030172 endocrine system disease Diseases 0.000 claims description 6
201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 6
208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 6
230000024949 interleukin-17 production Effects 0.000 claims description 6
201000000306 sarcoidosis Diseases 0.000 claims description 6
206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 5
206010008909 Chronic Hepatitis Diseases 0.000 claims description 5
206010009900 Colitis ulcerative Diseases 0.000 claims description 5
206010019755 Hepatitis chronic active Diseases 0.000 claims description 5
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 5
201000001263 Psoriatic Arthritis Diseases 0.000 claims description 5
208000036824 Psoriatic arthropathy Diseases 0.000 claims description 5
206010039085 Rhinitis allergic Diseases 0.000 claims description 5
208000021386 Sjogren Syndrome Diseases 0.000 claims description 5
201000006704 Ulcerative Colitis Diseases 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 5
201000010105 allergic rhinitis Diseases 0.000 claims description 5
208000010668 atopic eczema Diseases 0.000 claims description 5
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 5
125000005605 benzo group Chemical group 0.000 claims description 5
229940125904 compound 1 Drugs 0.000 claims description 5
229940126214 compound 3 Drugs 0.000 claims description 5
230000003704 interleukin-23 production Effects 0.000 claims description 5
230000003902 lesion Effects 0.000 claims description 5
210000004072 lung Anatomy 0.000 claims description 5
230000035755 proliferation Effects 0.000 claims description 5
229910052721 tungsten Inorganic materials 0.000 claims description 5
229910052720 vanadium Inorganic materials 0.000 claims description 5
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 claims description 4
SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims description 4
WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 claims description 4
QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims description 4
IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims description 4
ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims description 4
UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 claims description 4
YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 claims description 4
TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 claims description 4
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 4
208000023328 Basedow disease Diseases 0.000 claims description 4
206010006895 Cachexia Diseases 0.000 claims description 4
229940126657 Compound 17 Drugs 0.000 claims description 4
208000009329 Graft vs Host Disease Diseases 0.000 claims description 4
206010018691 Granuloma Diseases 0.000 claims description 4
208000015023 Graves' disease Diseases 0.000 claims description 4
208000016604 Lyme disease Diseases 0.000 claims description 4
201000009906 Meningitis Diseases 0.000 claims description 4
OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 claims description 4
241000721454 Pemphigus Species 0.000 claims description 4
208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 4
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 4
208000024799 Thyroid disease Diseases 0.000 claims description 4
206010047642 Vitiligo Diseases 0.000 claims description 4
LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 claims description 4
208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 4
201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 4
230000007815 allergy Effects 0.000 claims description 4
208000007502 anemia Diseases 0.000 claims description 4
XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 claims description 4
201000004982 autoimmune uveitis Diseases 0.000 claims description 4
210000000988 bone and bone Anatomy 0.000 claims description 4
229940125773 compound 10 Drugs 0.000 claims description 4
229940126543 compound 14 Drugs 0.000 claims description 4
229940125758 compound 15 Drugs 0.000 claims description 4
229940126142 compound 16 Drugs 0.000 claims description 4
229940125782 compound 2 Drugs 0.000 claims description 4
229940125810 compound 20 Drugs 0.000 claims description 4
229940126086 compound 21 Drugs 0.000 claims description 4
229940126208 compound 22 Drugs 0.000 claims description 4
229940125961 compound 24 Drugs 0.000 claims description 4
229940125846 compound 25 Drugs 0.000 claims description 4
229940125851 compound 27 Drugs 0.000 claims description 4
229940125898 compound 5 Drugs 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
229940079593 drug Drugs 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims description 4
208000006454 hepatitis Diseases 0.000 claims description 4
231100000283 hepatitis Toxicity 0.000 claims description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 claims description 4
206010023332 keratitis Diseases 0.000 claims description 4
201000010666 keratoconjunctivitis Diseases 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 4
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
229960004889 salicylic acid Drugs 0.000 claims description 4
206010043554 thrombocytopenia Diseases 0.000 claims description 4
208000021510 thyroid gland disease Diseases 0.000 claims description 4
206010043778 thyroiditis Diseases 0.000 claims description 4
208000009304 Acute Kidney Injury Diseases 0.000 claims description 3
208000026872 Addison Disease Diseases 0.000 claims description 3
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 3
201000004384 Alopecia Diseases 0.000 claims description 3
206010002198 Anaphylactic reaction Diseases 0.000 claims description 3
208000032467 Aplastic anaemia Diseases 0.000 claims description 3
208000037157 Azotemia Diseases 0.000 claims description 3
208000002691 Choroiditis Diseases 0.000 claims description 3
206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
201000003883 Cystic fibrosis Diseases 0.000 claims description 3
208000006313 Delayed Hypersensitivity Diseases 0.000 claims description 3
206010060742 Endocrine ophthalmopathy Diseases 0.000 claims description 3
201000009273 Endometriosis Diseases 0.000 claims description 3
206010018364 Glomerulonephritis Diseases 0.000 claims description 3
208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 3
206010019315 Heart transplant rejection Diseases 0.000 claims description 3
208000032843 Hemorrhage Diseases 0.000 claims description 3
208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 3
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 3
208000029523 Interstitial Lung disease Diseases 0.000 claims description 3
206010058142 Intestine transplant rejection Diseases 0.000 claims description 3
206010022941 Iridocyclitis Diseases 0.000 claims description 3
206010023439 Kidney transplant rejection Diseases 0.000 claims description 3
206010024715 Liver transplant rejection Diseases 0.000 claims description 3
206010051604 Lung transplant rejection Diseases 0.000 claims description 3
208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
206010060880 Monoclonal gammopathy Diseases 0.000 claims description 3
206010029333 Neurosis Diseases 0.000 claims description 3
208000003435 Optic Neuritis Diseases 0.000 claims description 3
206010053869 POEMS syndrome Diseases 0.000 claims description 3
206010049169 Pancreas transplant rejection Diseases 0.000 claims description 3
206010033645 Pancreatitis Diseases 0.000 claims description 3
206010033647 Pancreatitis acute Diseases 0.000 claims description 3
201000011152 Pemphigus Diseases 0.000 claims description 3
206010065159 Polychondritis Diseases 0.000 claims description 3
206010036105 Polyneuropathy Diseases 0.000 claims description 3
208000003971 Posterior uveitis Diseases 0.000 claims description 3
206010036774 Proctitis Diseases 0.000 claims description 3
208000003782 Raynaud disease Diseases 0.000 claims description 3
208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
208000033626 Renal failure acute Diseases 0.000 claims description 3
206010039094 Rhinitis perennial Diseases 0.000 claims description 3
206010062164 Seronegative arthritis Diseases 0.000 claims description 3
208000007107 Stomach Ulcer Diseases 0.000 claims description 3
208000004732 Systemic Vasculitis Diseases 0.000 claims description 3
206010053614 Type III immune complex mediated reaction Diseases 0.000 claims description 3
208000024780 Urticaria Diseases 0.000 claims description 3
206010046851 Uveitis Diseases 0.000 claims description 3
206010046914 Vaginal infection Diseases 0.000 claims description 3
201000008100 Vaginitis Diseases 0.000 claims description 3
208000018839 Wilson disease Diseases 0.000 claims description 3
201000011040 acute kidney failure Diseases 0.000 claims description 3
201000003229 acute pancreatitis Diseases 0.000 claims description 3
208000012998 acute renal failure Diseases 0.000 claims description 3
208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
208000002029 allergic contact dermatitis Diseases 0.000 claims description 3
208000004631 alopecia areata Diseases 0.000 claims description 3
208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims description 3
208000003455 anaphylaxis Diseases 0.000 claims description 3
201000004612 anterior uveitis Diseases 0.000 claims description 3
230000009227 antibody-mediated cytotoxicity Effects 0.000 claims description 3
208000002399 aphthous stomatitis Diseases 0.000 claims description 3
208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 claims description 3
208000034158 bleeding Diseases 0.000 claims description 3
230000000740 bleeding effect Effects 0.000 claims description 3
210000001185 bone marrow Anatomy 0.000 claims description 3
229910052796 boron Inorganic materials 0.000 claims description 3
208000020670 canker sore Diseases 0.000 claims description 3
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
210000000845 cartilage Anatomy 0.000 claims description 3
208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
229940125833 compound 23 Drugs 0.000 claims description 3
208000010247 contact dermatitis Diseases 0.000 claims description 3
208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 3
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
201000002491 encephalomyelitis Diseases 0.000 claims description 3
238000011156 evaluation Methods 0.000 claims description 3
230000001605 fetal effect Effects 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
201000005917 gastric ulcer Diseases 0.000 claims description 3
208000024908 graft versus host disease Diseases 0.000 claims description 3
238000001631 haemodialysis Methods 0.000 claims description 3
230000000322 hemodialysis Effects 0.000 claims description 3
230000002949 hemolytic effect Effects 0.000 claims description 3
239000007943 implant Substances 0.000 claims description 3
208000014674 injury Diseases 0.000 claims description 3
208000036971 interstitial lung disease 2 Diseases 0.000 claims description 3
230000003834 intracellular effect Effects 0.000 claims description 3
230000005865 ionizing radiation Effects 0.000 claims description 3
201000004614 iritis Diseases 0.000 claims description 3
230000002503 metabolic effect Effects 0.000 claims description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
201000008383 nephritis Diseases 0.000 claims description 3
208000009928 nephrosis Diseases 0.000 claims description 3
231100001027 nephrosis Toxicity 0.000 claims description 3
208000015238 neurotic disease Diseases 0.000 claims description 3
210000000440 neutrophil Anatomy 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
230000000849 parathyroid Effects 0.000 claims description 3
201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
231100000572 poisoning Toxicity 0.000 claims description 3
230000000607 poisoning effect Effects 0.000 claims description 3
230000007824 polyneuropathy Effects 0.000 claims description 3
201000011461 pre-eclampsia Diseases 0.000 claims description 3
230000035945 sensitivity Effects 0.000 claims description 3
208000007056 sickle cell anemia Diseases 0.000 claims description 3
206010040882 skin lesion Diseases 0.000 claims description 3
231100000444 skin lesion Toxicity 0.000 claims description 3
210000000813 small intestine Anatomy 0.000 claims description 3
210000001541 thymus gland Anatomy 0.000 claims description 3
230000001988 toxicity Effects 0.000 claims description 3
231100000419 toxicity Toxicity 0.000 claims description 3
230000008733 trauma Effects 0.000 claims description 3
208000025883 type III hypersensitivity disease Diseases 0.000 claims description 3
230000005951 type IV hypersensitivity Effects 0.000 claims description 3
208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 3
208000009852 uremia Diseases 0.000 claims description 3
230000002485 urinary effect Effects 0.000 claims description 3
206010003399 Arthropod bite Diseases 0.000 claims description 2
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 2
208000019872 Drug Eruptions Diseases 0.000 claims description 2
231100000360 alopecia Toxicity 0.000 claims description 2
125000004104 aryloxy group Chemical group 0.000 claims description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
150000004677 hydrates Chemical class 0.000 claims description 2
208000010125 myocardial infarction Diseases 0.000 claims description 2
230000003204 osmotic effect Effects 0.000 claims description 2
210000001539 phagocyte Anatomy 0.000 claims description 2
230000009885 systemic effect Effects 0.000 claims description 2
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
238000007879 vasectomy Methods 0.000 claims description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
206010012689 Diabetic retinopathy Diseases 0.000 claims 1
206010037660 Pyrexia Diseases 0.000 claims 1
230000005784 autoimmunity Effects 0.000 claims 1
206010025135 lupus erythematosus Diseases 0.000 claims 1
230000003211 malignant effect Effects 0.000 claims 1
208000037941 meningococcal disease Diseases 0.000 claims 1
108010065637 Interleukin-23 Proteins 0.000 abstract description 31
229940124830 IL-23 Drugs 0.000 abstract description 30
102100036678 Interleukin-27 subunit alpha Human genes 0.000 abstract description 15
238000011282 treatment Methods 0.000 abstract description 13
229940117681 interleukin-12 Drugs 0.000 description 36
238000005481 NMR spectroscopy Methods 0.000 description 34
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 31
102000013264 Interleukin-23 Human genes 0.000 description 30
238000002360 preparation method Methods 0.000 description 30
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
239000000243 solution Substances 0.000 description 26
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 23
239000000203 mixture Substances 0.000 description 21
230000014509 gene expression Effects 0.000 description 19
208000027866 inflammatory disease Diseases 0.000 description 19
239000002904 solvent Substances 0.000 description 19
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 18
238000012360 testing method Methods 0.000 description 18
210000001744 T-lymphocyte Anatomy 0.000 description 16
239000007787 solid Substances 0.000 description 16
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
239000002158 endotoxin Substances 0.000 description 14
229920006008 lipopolysaccharide Polymers 0.000 description 14
235000019439 ethyl acetate Nutrition 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 12
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
238000003818 flash chromatography Methods 0.000 description 12
208000026278 immune system disease Diseases 0.000 description 12
125000001424 substituent group Chemical group 0.000 description 12
102000004127 Cytokines Human genes 0.000 description 10
108090000695 Cytokines Proteins 0.000 description 10
108010074328 Interferon-gamma Proteins 0.000 description 10
OLNJUISKUQQNIM-UHFFFAOYSA-N indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=CNC2=C1 OLNJUISKUQQNIM-UHFFFAOYSA-N 0.000 description 10
230000005764 inhibitory process Effects 0.000 description 10
230000019734 interleukin-12 production Effects 0.000 description 10
230000002829 reductive effect Effects 0.000 description 10
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
102100037850 Interferon gamma Human genes 0.000 description 9
210000000447 Th1 cell Anatomy 0.000 description 9
230000001363 autoimmune Effects 0.000 description 9
125000005842 heteroatom Chemical group 0.000 description 9
239000000047 product Substances 0.000 description 9
239000011541 reaction mixture Substances 0.000 description 9
239000000725 suspension Substances 0.000 description 9
0 Cc1cccc(C=NNc2c(*)c(N3CCOCC3)nc(-c3ccccc3)n2)c1 Chemical compound Cc1cccc(C=NNc2c(*)c(N3CCOCC3)nc(-c3ccccc3)n2)c1 0.000 description 8
239000002253 acid Substances 0.000 description 8
239000012267 brine Substances 0.000 description 8
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
239000003981 vehicle Substances 0.000 description 8
206010003246 arthritis Diseases 0.000 description 7
238000003556 assay Methods 0.000 description 7
210000002429 large intestine Anatomy 0.000 description 7
239000011734 sodium Substances 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
208000011231 Crohn disease Diseases 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
230000004069 differentiation Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
150000002148 esters Chemical class 0.000 description 6
210000004698 lymphocyte Anatomy 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
206010039073 rheumatoid arthritis Diseases 0.000 description 6
239000000126 substance Substances 0.000 description 6
239000006228 supernatant Substances 0.000 description 6
230000008961 swelling Effects 0.000 description 6
201000000596 systemic lupus erythematosus Diseases 0.000 description 6
OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 5
238000008157 ELISA kit Methods 0.000 description 5
208000009386 Experimental Arthritis Diseases 0.000 description 5
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
150000001408 amides Chemical class 0.000 description 5
125000002619 bicyclic group Chemical group 0.000 description 5
206010009887 colitis Diseases 0.000 description 5
239000000833 heterodimer Substances 0.000 description 5
125000001183 hydrocarbyl group Chemical group 0.000 description 5
125000002950 monocyclic group Chemical group 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
229910000104 sodium hydride Inorganic materials 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000005160 1H NMR spectroscopy Methods 0.000 description 4
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
101000852964 Homo sapiens Interleukin-27 subunit beta Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
208000022559 Inflammatory bowel disease Diseases 0.000 description 4
102100036712 Interleukin-27 subunit beta Human genes 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
241000699670 Mus sp. Species 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
230000009471 action Effects 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
125000001309 chloro group Chemical group Cl* 0.000 description 4
206010012601 diabetes mellitus Diseases 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
230000021547 interleukin-27 production Effects 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
230000000770 proinflammatory effect Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
125000000714 pyrimidinyl group Chemical group 0.000 description 4
239000000377 silicon dioxide Substances 0.000 description 4
239000003826 tablet Substances 0.000 description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
DPVIABCMTHHTGB-UHFFFAOYSA-N 2,4,6-trichloropyrimidine Chemical compound ClC1=CC(Cl)=NC(Cl)=N1 DPVIABCMTHHTGB-UHFFFAOYSA-N 0.000 description 3
QGGYMWHOBGSQCF-UHFFFAOYSA-N 4-(2,6-dichloropyrimidin-4-yl)morpholine Chemical compound ClC1=NC(Cl)=CC(N2CCOCC2)=N1 QGGYMWHOBGSQCF-UHFFFAOYSA-N 0.000 description 3
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 3
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
208000031845 Pernicious anaemia Diseases 0.000 description 3
206010036030 Polyarthritis Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
230000003833 cell viability Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000013078 crystal Substances 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000002270 dispersing agent Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
231100000673 dose–response relationship Toxicity 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
125000000524 functional group Chemical group 0.000 description 3
238000001802 infusion Methods 0.000 description 3
210000001616 monocyte Anatomy 0.000 description 3
125000002971 oxazolyl group Chemical group 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
208000030428 polyarticular arthritis Diseases 0.000 description 3
238000000746 purification Methods 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
238000003756 stirring Methods 0.000 description 3
125000001544 thienyl group Chemical group 0.000 description 3
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
238000010626 work up procedure Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
BBVOKSGQRQRJBP-UHFFFAOYSA-N (2-butoxy-6-morpholin-4-ylpyrimidin-4-yl)hydrazine Chemical compound CCCCOC1=NC(NN)=CC(N2CCOCC2)=N1 BBVOKSGQRQRJBP-UHFFFAOYSA-N 0.000 description 2
IXNLCHZSHODPBG-UHFFFAOYSA-N (6-morpholin-4-yl-2-pyridin-3-yloxypyrimidin-4-yl)hydrazine Chemical compound N=1C(NN)=CC(N2CCOCC2)=NC=1OC1=CC=CN=C1 IXNLCHZSHODPBG-UHFFFAOYSA-N 0.000 description 2
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
UWNADWZGEHDQAB-UHFFFAOYSA-N 2,5-dimethylhexane Chemical group CC(C)CCC(C)C UWNADWZGEHDQAB-UHFFFAOYSA-N 0.000 description 2
GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 2
FEBPMHLKIHWNRE-UHFFFAOYSA-N 4-(2-butoxy-6-chloropyrimidin-4-yl)morpholine Chemical compound CCCCOC1=NC(Cl)=CC(N2CCOCC2)=N1 FEBPMHLKIHWNRE-UHFFFAOYSA-N 0.000 description 2
PYZBNJXHCXPIPK-UHFFFAOYSA-N 4-(4-chloro-6-morpholin-4-ylpyrimidin-2-yl)butan-1-ol Chemical compound OCCCCC1=NC(Cl)=CC(N2CCOCC2)=N1 PYZBNJXHCXPIPK-UHFFFAOYSA-N 0.000 description 2
OYEWVBVCBDKNLH-UHFFFAOYSA-N 4-(6-chloro-2-pyridin-3-yloxypyrimidin-4-yl)morpholine Chemical compound N=1C(Cl)=CC(N2CCOCC2)=NC=1OC1=CC=CN=C1 OYEWVBVCBDKNLH-UHFFFAOYSA-N 0.000 description 2
PZQCOVTVWXDXMN-UHFFFAOYSA-N 4-[6-chloro-2-(3-methoxypropyl)pyrimidin-4-yl]morpholine Chemical compound COCCCC1=NC(Cl)=CC(N2CCOCC2)=N1 PZQCOVTVWXDXMN-UHFFFAOYSA-N 0.000 description 2
ADPQSJMHXUREJN-UHFFFAOYSA-N 4-chloro-6-(2-pyridin-3-yloxyethoxy)-1h-pyrimidin-4-amine Chemical compound NC1(Cl)NC=NC(OCCOC=2C=NC=CC=2)=C1 ADPQSJMHXUREJN-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
206010012438 Dermatitis atopic Diseases 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
208000002633 Febrile Neutropenia Diseases 0.000 description 2
206010016654 Fibrosis Diseases 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
101001066288 Gallus gallus GATA-binding factor 3 Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
241000282412 Homo Species 0.000 description 2
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 2
102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 description 2
101710103840 Interleukin-12 receptor subunit beta-2 Proteins 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000035809 Lymphohistiocytosis Diseases 0.000 description 2
206010058858 Meningococcal bacteraemia Diseases 0.000 description 2
241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
206010058461 Orchitis noninfective Diseases 0.000 description 2
241000286209 Phasianidae Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
239000012979 RPMI medium Substances 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
150000001299 aldehydes Chemical class 0.000 description 2
150000003973 alkyl amines Chemical class 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
235000010323 ascorbic acid Nutrition 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
201000008937 atopic dermatitis Diseases 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000002585 base Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
239000011575 calcium Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
150000004657 carbamic acid derivatives Chemical class 0.000 description 2
125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
208000037976 chronic inflammation Diseases 0.000 description 2
208000037893 chronic inflammatory disorder Diseases 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
210000001072 colon Anatomy 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000003995 emulsifying agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
NDXKVKIBQJBDCX-UHFFFAOYSA-N ethyl 4-(4-chloro-6-morpholin-4-ylpyrimidin-2-yl)butanoate Chemical compound CCOC(=O)CCCC1=NC(Cl)=CC(N2CCOCC2)=N1 NDXKVKIBQJBDCX-UHFFFAOYSA-N 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
125000002541 furyl group Chemical group 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
102000043557 human IFNG Human genes 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 2
125000005945 imidazopyridyl group Chemical group 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
238000005462 in vivo assay Methods 0.000 description 2
125000001041 indolyl group Chemical group 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
239000000178 monomer Substances 0.000 description 2
210000000822 natural killer cell Anatomy 0.000 description 2
125000006574 non-aromatic ring group Chemical group 0.000 description 2
239000012038 nucleophile Substances 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
230000000242 pagocytic effect Effects 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
229910052698 phosphorus Inorganic materials 0.000 description 2
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
125000000168 pyrrolyl group Chemical group 0.000 description 2
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
238000003118 sandwich ELISA Methods 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
210000004988 splenocyte Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
125000006727 (C1-C6) alkenyl group Chemical group 0.000 description 1
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
AKAIWNDBVZJOAJ-UHFFFAOYSA-N 1,4-dithiine Chemical compound S1C=CSC=C1 AKAIWNDBVZJOAJ-UHFFFAOYSA-N 0.000 description 1
HUZPZQIUPMNTPZ-UHFFFAOYSA-N 1-(1H-indol-3-yl)-N-[6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]oxymethanimine Chemical compound N=1C(ON=CC=2C3=CC=CC=C3NC=2)=CC(N2CCOCC2)=NC=1OCCC1=CC=CC=N1 HUZPZQIUPMNTPZ-UHFFFAOYSA-N 0.000 description 1
DXXTXZSTXSQSHK-UHFFFAOYSA-N 1-(3-methylphenyl)-n-[6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-yl]oxymethanimine Chemical compound CC1=CC=CC(C=NOC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 DXXTXZSTXSQSHK-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
NEFAZJJIHDDXKM-UHFFFAOYSA-N 2,3-dimethyl-1h-indol-5-amine Chemical compound C1=C(N)C=C2C(C)=C(C)NC2=C1 NEFAZJJIHDDXKM-UHFFFAOYSA-N 0.000 description 1
GPLGXKXOZXCNOM-UHFFFAOYSA-N 2,3-dimethyl-n-[4-morpholin-4-yl-6-(2-pyridin-3-yloxyethoxy)pyrimidin-2-yl]-1h-indol-5-amine Chemical compound C1=C2C(C)=C(C)NC2=CC=C1NC(N=C(C=1)N2CCOCC2)=NC=1OCCOC1=CC=CN=C1 GPLGXKXOZXCNOM-UHFFFAOYSA-N 0.000 description 1
GWGBNENHEGYJSN-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GWGBNENHEGYJSN-UHFFFAOYSA-N 0.000 description 1
KFXDYZXVIHNBFD-UHFFFAOYSA-N 2-(thian-2-ylsulfonyl)thiane Chemical compound C1CCCSC1S(=O)(=O)C1CCCCS1 KFXDYZXVIHNBFD-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
DQEUFPARIOFOAI-UHFFFAOYSA-N 2-propan-2-ylpropanedioic acid Chemical compound CC(C)C(C(O)=O)C(O)=O DQEUFPARIOFOAI-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
YHWMFDLNZGIJSD-UHFFFAOYSA-N 2h-1,4-oxazine Chemical compound C1OC=CN=C1 YHWMFDLNZGIJSD-UHFFFAOYSA-N 0.000 description 1
UEIZUEWXLJOVLD-UHFFFAOYSA-N 3-(1-methylpyrrolidin-3-yl)pyridine Chemical compound C1N(C)CCC1C1=CC=CN=C1 UEIZUEWXLJOVLD-UHFFFAOYSA-N 0.000 description 1
QTLOCDAVUGANNM-UHFFFAOYSA-N 3-(4-chloro-6-morpholin-4-ylpyrimidin-2-yl)propan-1-ol Chemical compound OCCCC1=NC(Cl)=CC(N2CCOCC2)=N1 QTLOCDAVUGANNM-UHFFFAOYSA-N 0.000 description 1
BVJUOJCJCHNXJG-UHFFFAOYSA-N 3-[6-[2-[(3-methylphenyl)methylidene]hydrazinyl]-4-morpholin-4-ylpyridin-2-yl]propyl cyclohexanecarboxylate Chemical compound CC1=CC=CC(C=NNC=2N=C(CCCOC(=O)C3CCCCC3)C=C(C=2)N2CCOCC2)=C1 BVJUOJCJCHNXJG-UHFFFAOYSA-N 0.000 description 1
JJCGQPJPYPZPKN-UHFFFAOYSA-N 4,6-dichloro-5-methyl-2-phenylpyrimidine Chemical compound N1=C(Cl)C(C)=C(Cl)N=C1C1=CC=CC=C1 JJCGQPJPYPZPKN-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
IMMRNZXCSNAWCW-UHFFFAOYSA-N 4-(6-chloro-5-methyl-2-phenylpyrimidin-4-yl)morpholine Chemical compound CC1=C(Cl)N=C(C=2C=CC=CC=2)N=C1N1CCOCC1 IMMRNZXCSNAWCW-UHFFFAOYSA-N 0.000 description 1
KEGSVBDVTMTROH-UHFFFAOYSA-N 4-[4-[2-(1H-indol-3-ylmethylidene)hydrazinyl]-6-morpholin-4-ylpyrimidin-2-yl]butan-1-ol Chemical compound N=1C(CCCCO)=NC(NN=CC=2C3=CC=CC=C3NC=2)=CC=1N1CCOCC1 KEGSVBDVTMTROH-UHFFFAOYSA-N 0.000 description 1
APRZHQXAAWPYHS-UHFFFAOYSA-N 4-[5-[3-(carboxymethoxy)phenyl]-3-(4,5-dimethyl-1,3-thiazol-2-yl)tetrazol-3-ium-2-yl]benzenesulfonate Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=C(OCC(O)=O)C=CC=2)=NN1C1=CC=C(S([O-])(=O)=O)C=C1 APRZHQXAAWPYHS-UHFFFAOYSA-N 0.000 description 1
LUBQTVNMICNVKR-UHFFFAOYSA-N 4-[6-chloro-2-[3-(3,4-dimethoxyphenyl)propyl]pyrimidin-4-yl]morpholine Chemical compound C1=C(OC)C(OC)=CC=C1CCCC1=NC(Cl)=CC(N2CCOCC2)=N1 LUBQTVNMICNVKR-UHFFFAOYSA-N 0.000 description 1
DYSPXUPJUUHGBU-UHFFFAOYSA-N 4-hydroxy-5-methyl-2-phenyl-1h-pyrimidin-6-one Chemical compound N1=C(O)C(C)=C(O)N=C1C1=CC=CC=C1 DYSPXUPJUUHGBU-UHFFFAOYSA-N 0.000 description 1
DUIMWXDLDBNUFD-UHFFFAOYSA-N 4-pyrimidin-2-ylmorpholine Chemical compound C1COCCN1C1=NC=CC=N1 DUIMWXDLDBNUFD-UHFFFAOYSA-N 0.000 description 1
PHPOFLKWFPOUHW-UHFFFAOYSA-N 6-chloro-2-(2-pyridin-3-yloxyethoxy)pyrimidin-4-amine Chemical compound NC1=CC(Cl)=NC(OCCOC=2C=NC=CC=2)=N1 PHPOFLKWFPOUHW-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
NRLQBVLOUUPAMI-UHFFFAOYSA-N 8-[3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxybenzoyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)N2CCC3(CNC(O3)=O)CC2)C=CC=1 NRLQBVLOUUPAMI-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003402 Arthropod sting Diseases 0.000 description 1
206010071155 Autoimmune arthritis Diseases 0.000 description 1
208000030767 Autoimmune encephalitis Diseases 0.000 description 1
208000015338 Autoimmune hepatitis type 1 Diseases 0.000 description 1
206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 1
208000009137 Behcet syndrome Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
FUVBZPIJWSRWCZ-DHRITJCHSA-N CC1(C)OC(COc2nc(N/N=C/c3c[nH]c4c3cccc4)cc(N3CCOCC3)n2)CO1 Chemical compound CC1(C)OC(COc2nc(N/N=C/c3c[nH]c4c3cccc4)cc(N3CCOCC3)n2)CO1 FUVBZPIJWSRWCZ-DHRITJCHSA-N 0.000 description 1
JXRWXCCZTUFGMG-BUVRLJJBSA-N CCCCNc1nc(N/N=C/c2c[nH]c3c2cccc3)cc(N2CCOCC2)n1 Chemical compound CCCCNc1nc(N/N=C/c2c[nH]c3c2cccc3)cc(N2CCOCC2)n1 JXRWXCCZTUFGMG-BUVRLJJBSA-N 0.000 description 1
101100346189 Caenorhabditis elegans mpc-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000700198 Cavia Species 0.000 description 1
NCIAXDCSYBXVGG-OEAKJJBVSA-N Cc1cccc(/C=N/Nc2cc(N3CCOCC3)nc(Oc3cccnc3)n2)c1 Chemical compound Cc1cccc(/C=N/Nc2cc(N3CCOCC3)nc(Oc3cccnc3)n2)c1 NCIAXDCSYBXVGG-OEAKJJBVSA-N 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
208000017667 Chronic Disease Diseases 0.000 description 1
PRTGBGXVQVLMGW-UHFFFAOYSA-N Cl.C(C1=CC=CC=C1)(=N)N.CC=1C=C(C=NNC2=NC(=NC(=C2C)N2CCOCC2)C2=CC=CC=C2)C=CC1 Chemical compound Cl.C(C1=CC=CC=C1)(=N)N.CC=1C=C(C=NNC2=NC(=NC(=C2C)N2CCOCC2)C2=CC=CC=C2)C=CC1 PRTGBGXVQVLMGW-UHFFFAOYSA-N 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920000858 Cyclodextrin Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
102000007260 Deoxyribonuclease I Human genes 0.000 description 1
108010008532 Deoxyribonuclease I Proteins 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
208000037487 Endotoxemia Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
IYXGSMUGOJNHAZ-UHFFFAOYSA-N Ethyl malonate Chemical compound CCOC(=O)CC(=O)OCC IYXGSMUGOJNHAZ-UHFFFAOYSA-N 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
206010058872 Fungal sepsis Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
208000007465 Giant cell arteritis Diseases 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
239000007818 Grignard reagent Substances 0.000 description 1
208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
101000713602 Homo sapiens T-box transcription factor TBX21 Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
206010022491 Insulin resistant diabetes Diseases 0.000 description 1
102100022338 Integrin alpha-M Human genes 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical class [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
206010049567 Miller Fisher syndrome Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
208000003926 Myelitis Diseases 0.000 description 1
208000009525 Myocarditis Diseases 0.000 description 1
YCOJPWKHMBNLMD-UHFFFAOYSA-N N-(1H-indol-3-ylmethylideneamino)-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound N=1C(NN=CC=2C3=CC=CC=C3NC=2)=CC(N2CCOCC2)=NC=1OCCC1=CC=CC=N1 YCOJPWKHMBNLMD-UHFFFAOYSA-N 0.000 description 1
SWHHIADRBZCQSZ-UHFFFAOYSA-N N-(1H-indol-3-ylmethylideneamino)-6-morpholin-4-yl-2-(2-pyridin-3-yloxyethoxy)pyrimidin-4-amine Chemical compound C=1C=CN=CC=1OCCOC(N=1)=NC(NN=CC=2C3=CC=CC=C3NC=2)=CC=1N1CCOCC1 SWHHIADRBZCQSZ-UHFFFAOYSA-N 0.000 description 1
UXLWGURZIXHGPC-UHFFFAOYSA-N N-(1H-indol-3-ylmethylideneamino)-6-morpholin-4-yl-2-(3-pyridin-2-ylpropyl)pyrimidin-4-amine Chemical compound N=1C(NN=CC=2C3=CC=CC=C3NC=2)=CC(N2CCOCC2)=NC=1CCCC1=CC=CC=N1 UXLWGURZIXHGPC-UHFFFAOYSA-N 0.000 description 1
OJWVOLDPANZGKJ-UHFFFAOYSA-N N-[1-(1H-indol-3-yl)ethylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound C=1NC2=CC=CC=C2C=1C(C)=NNC(N=1)=CC(N2CCOCC2)=NC=1OCCC1=CC=CC=N1 OJWVOLDPANZGKJ-UHFFFAOYSA-N 0.000 description 1
150000007945 N-acyl ureas Chemical class 0.000 description 1
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
206010061876 Obstruction Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
101800001157 Protein p28 Proteins 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
206010053879 Sepsis syndrome Diseases 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
241000607720 Serratia Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000006045 Spondylarthropathies Diseases 0.000 description 1
201000002661 Spondylitis Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
102100036840 T-box transcription factor TBX21 Human genes 0.000 description 1
210000000662 T-lymphocyte subset Anatomy 0.000 description 1
229920002253 Tannate Polymers 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
PGJIEVDZEWUMSA-UHFFFAOYSA-N [2-[3-(3,4-dimethoxyphenyl)propyl]-6-morpholin-4-ylpyrimidin-4-yl]hydrazine Chemical compound C1=C(OC)C(OC)=CC=C1CCCC1=NC(NN)=CC(N2CCOCC2)=N1 PGJIEVDZEWUMSA-UHFFFAOYSA-N 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
208000024716 acute asthma Diseases 0.000 description 1
230000004721 adaptive immunity Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000003282 alkyl amino group Chemical group 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000013459 approach Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
230000002917 arthritic effect Effects 0.000 description 1
125000001769 aryl amino group Chemical group 0.000 description 1
210000001815 ascending colon Anatomy 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 description 1
125000003828 azulenyl group Chemical group 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
239000011324 bead Substances 0.000 description 1
238000005452 bending Methods 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
150000008107 benzenesulfonic acids Chemical class 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000011116 calcium hydroxide Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
235000013877 carbamide Nutrition 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
150000004649 carbonic acid derivatives Chemical group 0.000 description 1
238000003763 carbonization Methods 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
AVPBPSOSZLWRDN-UHFFFAOYSA-M chloropalladium(1+);methanidylbenzene;triphenylphosphane Chemical compound [Pd+]Cl.[CH2-]C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 AVPBPSOSZLWRDN-UHFFFAOYSA-M 0.000 description 1
208000023819 chronic asthma Diseases 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
230000008951 colonic inflammation Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000013068 control sample Substances 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000004090 cyclononenyl group Chemical group C1(=CCCCCCCC1)* 0.000 description 1
125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001945 cyclooctatrienyl group Chemical group C1(=CC=CC=CCC1)* 0.000 description 1
125000000522 cyclooctenyl group Chemical group C1(=CCCCCCC1)* 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000058 cyclopentadienyl group Chemical group C1(=CC=CC1)* 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
210000001731 descending colon Anatomy 0.000 description 1
125000004663 dialkyl amino group Chemical group 0.000 description 1
150000004985 diamines Chemical class 0.000 description 1
125000004986 diarylamino group Chemical group 0.000 description 1
125000003963 dichloro group Chemical group Cl* 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
208000014793 distal colitis Diseases 0.000 description 1
210000004921 distal colon Anatomy 0.000 description 1
238000009826 distribution Methods 0.000 description 1
125000002228 disulfide group Chemical group 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
ZSWFCLXCOIISFI-UHFFFAOYSA-N endo-cyclopentadiene Natural products C1C=CC=C1 ZSWFCLXCOIISFI-UHFFFAOYSA-N 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
DLLJVQNYBYOKGS-UHFFFAOYSA-N ethoxyethane;pentane Chemical compound CCCCC.CCOCC DLLJVQNYBYOKGS-UHFFFAOYSA-N 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012997 ficoll-paque Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000003890 fistula Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
238000000684 flow cytometry Methods 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
229940050411 fumarate Drugs 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
229940114119 gentisate Drugs 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
210000002175 goblet cell Anatomy 0.000 description 1
150000004795 grignard reagents Chemical class 0.000 description 1
238000000227 grinding Methods 0.000 description 1
208000024963 hair loss Diseases 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
235000015220 hamburgers Nutrition 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000005457 ice water Substances 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
230000007574 infarction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
208000013256 infectious meningitis Diseases 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
244000000056 intracellular parasite Species 0.000 description 1
238000007917 intracranial administration Methods 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
238000011694 lewis rat Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
OVWYEQOVUDKZNU-UHFFFAOYSA-N m-tolualdehyde Chemical compound CC1=CC=CC(C=O)=C1 OVWYEQOVUDKZNU-UHFFFAOYSA-N 0.000 description 1
125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical class [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
235000012254 magnesium hydroxide Nutrition 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229940098895 maleic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
238000002493 microarray Methods 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
206010028537 myelofibrosis Diseases 0.000 description 1
RAPFWYGXEAVGSD-UHFFFAOYSA-N n-[(3-ethylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CCC1=CC=CC(C=NNC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 RAPFWYGXEAVGSD-UHFFFAOYSA-N 0.000 description 1
IHFMVPCBQXKWMI-UHFFFAOYSA-N n-[(3-methylphenyl)methylideneamino]-2-phenyl-6-thiomorpholin-4-ylpyrimidin-4-amine Chemical compound CC1=CC=CC(C=NNC=2N=C(N=C(C=2)N2CCSCC2)C=2C=CC=CC=2)=C1 IHFMVPCBQXKWMI-UHFFFAOYSA-N 0.000 description 1
HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 description 1
DQSQEGFLPNMCIC-UHFFFAOYSA-N n-[1-(3-methylphenyl)ethylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound C=1C=CC(C)=CC=1C(C)=NNC(N=1)=CC(N2CCOCC2)=NC=1OCCC1=CC=CC=N1 DQSQEGFLPNMCIC-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
210000003924 normoblast Anatomy 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
229940039748 oxalate Drugs 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
101800000857 p40 protein Proteins 0.000 description 1
MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 1
WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical class C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
229940014662 pantothenate Drugs 0.000 description 1
235000019161 pantothenic acid Nutrition 0.000 description 1
239000011713 pantothenic acid Substances 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
244000052769 pathogen Species 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
210000001986 peyer's patch Anatomy 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000001725 pyrenyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
IDXKTTNFXPPXJY-UHFFFAOYSA-N pyrimidin-1-ium;chloride Chemical compound Cl.C1=CN=CN=C1 IDXKTTNFXPPXJY-UHFFFAOYSA-N 0.000 description 1
150000003248 quinolines Chemical class 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000012827 research and development Methods 0.000 description 1
238000002271 resection Methods 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
125000006413 ring segment Chemical group 0.000 description 1
201000005404 rubella Diseases 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
239000000523 sample Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000011664 signaling Effects 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
210000004894 snout Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
PVGBHEUCHKGFQP-UHFFFAOYSA-M sodium;(1z)-n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylethanimidate Chemical compound [Na+].CC(=O)[N-]S(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-M 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
201000005671 spondyloarthropathy Diseases 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000001308 synthesis method Methods 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
206010043207 temporal arteritis Diseases 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000005888 tetrahydroindolyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
WCNFFKHKJLERFM-UHFFFAOYSA-N thiomorpholinyl sulfone group Chemical group N1(CCSCC1)S(=O)(=O)N1CCSCC1 WCNFFKHKJLERFM-UHFFFAOYSA-N 0.000 description 1
ZCAGUOCUDGWENZ-UHFFFAOYSA-N thiomorpholinyl sulfoxide group Chemical group N1(CCSCC1)S(=O)N1CCSCC1 ZCAGUOCUDGWENZ-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
210000003384 transverse colon Anatomy 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1
UGZADUVQMDAIAO-UHFFFAOYSA-L zinc hydroxide Chemical class [OH-].[OH-].[Zn+2] UGZADUVQMDAIAO-UHFFFAOYSA-L 0.000 description 1
XPARCVGSTPKNNR-UHFFFAOYSA-M zinc;ethyl butanoate;bromide Chemical compound [Zn+2].[Br-].CCOC(=O)CC[CH2-] XPARCVGSTPKNNR-UHFFFAOYSA-M 0.000 description 1